The number of Xarelto lawsuits filed under the federal Multidistrict Litigation (MDL) surged in June 2015 to over 400 filed lawsuits. This comes only 6 months after the formation of the MDL for Xarelto (MDL 2592) in federal court where all cases were centralized before Judge Fallon in Louisiana.
The manufacturer of Xarelto (Rivaroxaban), Bayer AG, and the marketing partner of Bayer in the US for Xarelto, Janssen (a Johnson & Johnson company) have seen the number of lawsuits alleging that the blood thinner caused severe uncontrollable bleeding events which caused injuries, hospitalizations and deaths, grow to over 400 cases.
The FDA Approvals For Xarelto (Rivaroxaban)
- a prophylaxis for valvular atrial fibrillation
- preventing blood clots in patients who had a knee or hip replacement
- preventing clots for patients at risk of deep vein thrombosis
- preventing stent thrombosis in patients with acute coronary syndrome
- and in general to reduce the risk of blood clots
The drug has dominated a market that has been estimated to be a $10 billion dollar market. The blood thinner entered the market as an alternative to Warfarin (Coumadine), which requires a much more strict monitoring of blood, to the extent that dosage amounts are customized to the patient’s needs, and patients are required to undergo regular blood testing, and observe a strict diet. Xarelto has been marketed as a once a day pill with no requirement of going to a blood clinic for blood monitoring.
Hundreds of Xarelto Lawsuits Filed
To date, the adverse events reported have included:
- Gastrointestinal bleeding or a GI bleed
- Pulmonary embolism
- brain bleeds
- spinal bleeds or epidural hematoma
- rectal, vaginal and colon bleeds
These bleeding events have caused many hospitalizations, and serious injuries such as stroke, heart attacks and paralysis. Unfortunately, many of the filed lawsuits involve the estates filing on behalf of a deceased family member. The major problem is that the medical community was never provided with instructions on how to reverse the anti coagulation effect of Xarelto if a bleed occurs. There is no known antidote to date, which is very different to Warfarin where a dosage of Vitamin K will cause blood clotting and stop the bleed.
As a result, many patients present to hospitals after an adverse event with internal bleeding and doctors must engage in many blood transfusions and implement extraordinary measures to save lives.
Given the sheer volume of prescriptions issued in the US, and the high percentage of adverse events, we believe that there may be close to 10,000 lawsuits in this litigation before bellwether trials begin.
For more information subscribe to The Legal Herald and stay tuned for the next update.